| 前收市價 | 32.92 |
| 開市 | 32.94 |
| 買盤 | 32.99 x 100 |
| 賣出價 | 33.04 x 100 |
| 今日波幅 | 32.45 - 33.09 |
| 52 週波幅 | 19.80 - 35.50 |
| 成交量 | |
| 平均成交量 | 781,140 |
| 市值 | 1.874B |
| Beta 值 (5 年，每月) | 0.81 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -6.31 |
| 業績公佈日 | 2024年8月01日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 44.00 |
ZacksWall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksAgios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
Insider MonkeyAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript May 2, 2024 Agios Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to Agios’ First Quarter 2024 Conference Call. [Operator Instructions] Please be advised that […]
